246 related articles for article (PubMed ID: 22447884)
1. Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.
Anderson AE; Lorenzi AR; Pratt A; Wooldridge T; Diboll J; Hilkens CM; Isaacs JD
Rheumatology (Oxford); 2012 Aug; 51(8):1397-406. PubMed ID: 22447884
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.
Ponchel F; Verburg RJ; Bingham SJ; Brown AK; Moore J; Protheroe A; Short K; Lawson CA; Morgan AW; Quinn M; Buch M; Field SL; Maltby SL; Masurel A; Douglas SH; Straszynski L; Fearon U; Veale DJ; Patel P; McGonagle D; Snowden J; Markham AF; Ma D; van Laar JM; Papadaki HA; Emery P; Isaacs JD
Arthritis Res Ther; 2005; 7(1):R80-92. PubMed ID: 15642146
[TBL] [Abstract][Full Text] [Related]
3. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.
Cooles FA; Anderson AE; Drayton T; Harry RA; Diboll J; Munro L; Thalayasingham N; Östör AJ; Isaacs JD
Arthritis Res Ther; 2016 Dec; 18(1):302. PubMed ID: 27993172
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
6. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
7. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
Isaacs JD; Greer S; Sharma S; Symmons D; Smith M; Johnston J; Waldmann H; Hale G; Hazleman BL
Arthritis Rheum; 2001 Sep; 44(9):1998-2008. PubMed ID: 11592360
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
9. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
10. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
[TBL] [Abstract][Full Text] [Related]
13. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation.
Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Gaya A; Martino R; Sierra J; Montserrat E
Exp Hematol; 2005 Oct; 33(10):1240-8. PubMed ID: 16219547
[TBL] [Abstract][Full Text] [Related]
15. The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients.
Scarsi M; Bossini N; Malacarne F; Valerio F; Sandrini S; Airò P
Transpl Int; 2010 Aug; 23(8):786-95. PubMed ID: 20136785
[TBL] [Abstract][Full Text] [Related]
16. Age-related thymic activity in adults following chemotherapy-induced lymphopenia.
Sfikakis PP; Gourgoulis GM; Moulopoulos LA; Kouvatseas G; Theofilopoulos AN; Dimopoulos MA
Eur J Clin Invest; 2005 Jun; 35(6):380-7. PubMed ID: 15948899
[TBL] [Abstract][Full Text] [Related]
17. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
Kanda Y; Oshima K; Kako S; Fukuda T; Uchida N; Miyamura K; Kondo Y; Nakao S; Nagafuji K; Miyamoto T; Kurokawa M; Okoshi Y; Chiba S; Ohashi Y; Takaue Y; Taniguchi S
Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
[TBL] [Abstract][Full Text] [Related]
18. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases.
Szodoray P; Varoczy L; Papp G; Barath S; Nakken B; Szegedi G; Zeher M
Scand J Rheumatol; 2012 Mar; 41(2):110-5. PubMed ID: 21936606
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of immune function in the first 3 years of life in thymectomized neonates during cardiac surgery.
Mancebo E; Clemente J; Sanchez J; Ruiz-Contreras J; De Pablos P; Cortezon S; Romo E; Paz-Artal E; Allende LM
Clin Exp Immunol; 2008 Dec; 154(3):375-83. PubMed ID: 18811694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
